Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
12 results
  • Cellular Therapy

23-278          Phase I

A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults with Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies

  • Multiple Myeloma, Cellular Therapy

23-360          Phase I

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)

  • Lymphoma, Cellular Therapy

21-422          Phase II

A Phase 2 Study of acalabrutinib in combination with lisocabtagene maraleucel in relapsed/refractory aggressive B-cell lymphomas

  • Multiple Myeloma, Cellular Therapy

18-604          Phase II

A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2).

  • Cellular Therapy, Multiple Myeloma

20-518          Phase I

A Phase I Clinical Trial with TriPRIL CAR T Cells for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  • Lymphoma, Cellular Therapy

23-474          Phase I

A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

  • Cellular Therapy, Multiple Myeloma

22-533          Phase II

A Phase II Study of CART-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  • Cellular Therapy

21-072          N/A

Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

  • Brain Tumors, Cellular Therapy

22-175          Phase I

INCIPIENT: INtraventricular CARv3-TEAM-E T Cells for PatIENTs with GBM

  • Lymphoma, Cellular Therapy

22-551          Phase II

Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 (in subjects with relapsed or refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL)

Showing 1 - 10 of 12 results